Short answer
TuHURA Biosciences, Inc./NV (HURA) filed its Q2 2026 10-Q quarterly report on Aug 14, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$9M
- +3.2% YoY · −22.4% QoQ
- EPS (diluted)
- −$0.14
- +33.3% YoY · −7.7% QoQ
Source: XBRL data from the TuHURA Biosciences, Inc./NV (HURA) Q2 2026 10-Q on SEC EDGAR. USD.
TuHURA Biosciences, Inc./NV Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New secured debt risk triggered by Parkview facility: $5.8 million borrowed at 12% interest, collateralized by substantially all company assets
- Most material liquidity risk: $1.0 million cash versus $13.0 million operating cash use during six months ended June 30, 2026
- Financing concentration risk: Parkview facility includes 6% default interest and repayment of 75% of net profits after two profitable quarters
- Clinical execution risk: IFx-2.0 Phase 3 trial and TBS-2025 development increased research and development spending to $11.9 million
- Continuing operating-loss risk: six-month net loss reached $16.7 million with accumulated deficit of $157.9 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TuHURA Biosciences, Inc./NV quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.